Updated on 2 August 2025
Organ-in-Cube: Next Generation Bionic Organ for Precision Medicine
About
Oncoimmunostics focuses on precision diagnostics and therapeutics by applying 3D bioprinting technology and AI to construct the patient-derived biomimetic disease microenvironment "Organ-in-Cube", which is the world’s first 3D-bioprinted pathologically bionic New Approach Methodology. “Organ-in-Cube” provides a fast, reliable pathway to personalized treatment selection while enabling standardized, high-throughput drug efficacy and toxicity evaluation. The product can also be used for preclinical drug efficacy evaluation, safety assessment, and pharmacokinetics for new drugs, which serves as a viable alternative to animal models and accelerates preclinical testing with accurate human-relevant data. “Organ-in-Cube” has a short manufacturing time, high biomimicry, high consistency and is superior to current organoid models and animal models.
Project Location
- China (Hong Kong)
Project Website
oncoimmunostics.com
Project Format
- Public-Private Partnership Project
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Operations
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 10,000,001 to 25,000,000 USD
Investment Capital Required
- 5,000,001 to 7,500,000 USD
Interested Format of Cooperation
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Private Equity & Venture Capital
- Risk Management (Financial Services)
Professional Services
- Business Valuation
- Consultancy
- Financial Advisory
- IP Related
- Risk Management
Attached files
Organisation
Hong Kong, China (Hong Kong)
Similar opportunities
Project
- No
- Bio-Tech
- Technology
- Joint Venture
- R&D Cooperation
- Project Planning
- Health Technology
- Seed & Pre-Series
- Financial Services
- 500,000 USD or Below
- Open for Negotiation
- Open for negotiation
- Professional Services
- Requisition of Service
- 1,000,001 to 2,500,000 USD
- Public-Private Partnership Project
Daisy Tan
Business Development Manager at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Business Valuation
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- Institutional Investment
- Feasibility Study Completed
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
Conjugated drug development platform
- No
- Bio-Tech
- Technology
- IP Related
- Consultancy
- Joint Venture
- Private Project
- R&D Cooperation
- Project Planning
- Health Technology
- Seed & Pre-Series
- Medical Technology
- Financial Services
- Business Valuation
- Open for Negotiation
- Open for negotiation
- Professional Services
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Private Equity & Venture Capital
Hoi Yee Chow
COO at Serilink Biotechnology Company Limited
Hong Kong, China (Hong Kong)